Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

This publication has 21 references indexed in Scilit:

• Safety and Potential of Drug Interactions of Caspofungin and Voriconazole in Multimorbid Patients
  Pharmacology, 2005
• International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
  European Journal of Clinical Microbiology & Infectious Diseases, 2005
• A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis
  Alimentary Pharmacology & Therapeutics, 2005
• Guidelines for Treatment of Candidiasis
  Clinical Infectious Diseases, 2004
• Echinocandin antifungal drugs
  The Lancet, 2003
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
  Antimicrobial Agents and Chemotherapy, 2003
• A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects
  Clinical Infectious Diseases, 2003
• Voriconazole
  Drugs, 2002
• Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
  Clinical Infectious Diseases, 2001
• A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia
  Clinical Infectious Diseases, 2000